赣龙抗栓胶囊联合抗血小板聚集药物治疗脑出血后急性脑梗死的临床效果

Clinical effect of Ganlong antithrombotic capsule combined with antiplatelet aggregation drugs in the treatment of acute cerebral infarction after intracerebral hemorrhage

目的探讨赣龙抗栓胶囊联合抗血小板聚集药物治疗脑出血后急性脑梗死的临床效果。方法选取2015年1月至2019年12月我院收治的90例脑出血后急性脑梗死患者为研究对象,按照不同治疗方法将其分为抗血小板聚集药物组(n=30,抗血小板聚集药物治疗)、赣龙抗栓胶囊组(n=30,赣龙抗栓胶囊治疗)、联合组(n=30,赣龙抗栓胶囊联合抗血小板聚集药物治疗)。比较三组的治疗效果、治疗前、后神经功能缺损情况、血管再通率及并发症发生情况。结果联合组的治疗总有效率显著高于抗血小板聚集药物组及赣龙抗栓胶囊组,差异具有统计学意义(P<0.05)。治疗后,三组的NIHSS评分均显著降低,且联合组低于抗血小板聚集药物组及赣龙抗栓胶囊组,差异具有统计学意义(P<0.05)。联合组的血管再通率显著高于抗血小板聚集药物组及赣龙抗栓胶囊组,差异具有统计学意义(P<0.05);三组的并发症总发生率比较,差异不具有统计学意义(P>0.05)。结论赣龙抗栓胶囊联合抗血小板聚集药物治疗脑出血后急性脑梗死的临床效果显著,可促使患者神经功能缺损情况明显改善,且血管再通率高,并发症少,值得临床全方位推广。

Objective To explore the clinical effect of Ganlong antithrombotic capsule combined with antiplatelet aggregation drugs in the treatment of acute cerebral infarction after intracerebral hemorrhage.Methods A total of 90 patients with acute cerebral infarction after intracerebral hemorrhage treated in our hospital from January 2015 to December 2019 were selected as the research objects.According to different treatment methods,the patients were divided into antiplatelet aggregation drug group(n=30,antiplatelet aggregation drug treatment),Ganlong antithrombotic capsule group(n=30,Ganlong antithrombotic capsule treatment),combined group(n=30,Ganlong antithrombotic capsule combined with antiplatelet aggregation drug treatment).The therapeutic effects,neurological deficits before and after treatment,vascular recanalization rate and complications of the three groups were compared.Results The total effective rate of treatment of the combined group were significantly higher than that of the antiplatelet aggregation drug group and the Ganlong antithrombotic capsule group,the differences were statistically significant(P<0.05).After treatment,the score of NIHSS of the three groups significantly decreased,and that in the combined group were lower than the antiplatelet aggregation drug group and the Ganlong antithrombotic capsule group,the differences were statistically significant(P<0.05).The vascular recanalization rate of the combined group were significantly higher than that of the antiplatelet aggregation drug group and the Ganlong antithrombotic capsule group,the differences were statistically significant(P<0.05);there was no significant difference in the total incidence of complications among the three groups(P>0.05).Conclusion Ganlong antithrombotic capsule combined with antiplatelet aggregation drug have significant clinical effects in the treatment of acute cerebral infarction after cerebral hemorrhage,it can promote the obvious improvement of patients'neurological deficits,and has high vascular recanalization rate and fewer complications,which is worthy of clinical comprehensive promotion.